Showing 19,821 - 19,840 results of 29,808 for search '(( 50 ((((we decrease) OR (mean decrease))) OR (a decrease)) ) OR ( i ex decrease ))', query time: 1.15s Refine Results
  1. 19821

    Table_5_Comprehensive analysis, immune, and cordycepin regulation for SOX9 expression in pan-cancers and the matched healthy tissues.xlsx by Shuguang Liu (87095)

    Published 2023
    “…It suggests that SOX9 expression is upregulated in the most cancer types (15/33) as a proto-oncogene. The fact that the decrease of SOX9 expression in SKCM and the increase of SOX9 in the cell lines of melanoma inhibit tumorigenicity in both mouse and human ex vivo models demonstrates that SOX9 could also be a tumor suppressor. …”
  2. 19822

    Table_4_Comprehensive analysis, immune, and cordycepin regulation for SOX9 expression in pan-cancers and the matched healthy tissues.xlsx by Shuguang Liu (87095)

    Published 2023
    “…It suggests that SOX9 expression is upregulated in the most cancer types (15/33) as a proto-oncogene. The fact that the decrease of SOX9 expression in SKCM and the increase of SOX9 in the cell lines of melanoma inhibit tumorigenicity in both mouse and human ex vivo models demonstrates that SOX9 could also be a tumor suppressor. …”
  3. 19823

    Table_6_Comprehensive analysis, immune, and cordycepin regulation for SOX9 expression in pan-cancers and the matched healthy tissues.xlsx by Shuguang Liu (87095)

    Published 2023
    “…It suggests that SOX9 expression is upregulated in the most cancer types (15/33) as a proto-oncogene. The fact that the decrease of SOX9 expression in SKCM and the increase of SOX9 in the cell lines of melanoma inhibit tumorigenicity in both mouse and human ex vivo models demonstrates that SOX9 could also be a tumor suppressor. …”
  4. 19824

    Table_3_Comprehensive analysis, immune, and cordycepin regulation for SOX9 expression in pan-cancers and the matched healthy tissues.xlsx by Shuguang Liu (87095)

    Published 2023
    “…It suggests that SOX9 expression is upregulated in the most cancer types (15/33) as a proto-oncogene. The fact that the decrease of SOX9 expression in SKCM and the increase of SOX9 in the cell lines of melanoma inhibit tumorigenicity in both mouse and human ex vivo models demonstrates that SOX9 could also be a tumor suppressor. …”
  5. 19825

    Pulmonary elastin pattern in the fetal rabbit model for CDH undergoing TO. by Aline Vuckovic (428961)

    Published 2013
    “…Open arrowheads indicate elastic fibers in the alveolar walls. <b>F</b>. The mean percentage of elastin-containing crests is decreased in DH lungs and restored by TO. …”
  6. 19826

    Talin-TS reveals forces in primary muscle fibers. by Sandra B. Lemke (6519788)

    Published 2019
    “…Scale bars are 50 μm in A and F and 20 μm in B–E and G–J. Scale bars in kymographs in F are 10 s and 2 μm. …”
  7. 19827
  8. 19828
  9. 19829

    Supplementary file 1_Pharmacokinetic and pharmacodynamic analyses of nafamostat in ECMO patients: comparing central vein and ECMO machine samples.pdf by Dong Hwan Lee (9908916)

    Published 2025
    “…NM was shown to inhibit the decrease in aPTT in the turnover model. In the patient model, the maximum inhibitory effect (Imax) of NM on the reduction of aPTT was 35.5%, and the concentration of NM required to achieve half of this maximum effect (IC50) was 350 μg/L. …”
  10. 19830

    Expanding HAART Treatment to All Currently Eligible Individuals under the 2008 IAS-USA Guidelines in British Columbia, Canada by Viviane D. Lima (118005)

    Published 2010
    “…</p><h3>Methodology</h3><p>We built a mathematical transmission model to investigate different HAART coverage scenarios (50%, 60%, 75% and 100%) of those medically eligible to receive HAART under the 2008 IAS guidelines. …”
  11. 19831

    AMPK activators reduce DVL3 in cervical cancer cells. by H. T. Kwan (291038)

    Published 2013
    “…(B) Upon treatment of A769662 at different doses (0, 50 and 100 μM), a 20-30% and 80%–100% reduction of DVL3 in SiHa and C33A could be observed respectively. …”
  12. 19832
  13. 19833

    Gene expression variability for multiple-parameter fluctuations. by Abhyudai Singh (503811)

    Published 2013
    “…Other model parameters taken as mRNA half-life = 2 hours, protein half-life = time-scale of parameter fluctuations = 10 hours, mean transcriptional burst size = 10 and mean mRNA copy number per cell = 50.…”
  14. 19834

    Table_1_Effect and Safety of Adding Metformin to Insulin Therapy in Treating Adolescents With Type 1 Diabetes Mellitus: An Updated Meta-Analysis of 10 Randomized Controlled Trials.... by Ying Liu (18461)

    Published 2022
    “…Results suggested that metformin significantly decreased the HbA1c level at 12 months (mean difference [MD])=-0.50, 95% confidence interval [CI]=-0.61 to -0.39, P < 0.01); BMI (kg/m<sup>2</sup>) at 3 months (MD=-1.05, 95%CI=-2.05 to -0.05, P=0.04); BMI z-score at 6 months (MD=-0.10, 95%CI=-0.14 to -0.06, P<0.01); and TIDD at 3 (MD=-0.13, 95%CI=-0.20 to -0.06, P<0.01), 6 (MD=-0.18, 95%CI=-0.25 to -0.11, P<0.01), and 12 (MD=-0.42, 95%CI=-0.49 to -0.35, P<0.01) months but significantly increased the risk of hypoglycemia events (risk ratio [RR]=3.13, 95%CI=1.05 to 9.32, P=0.04) and GIAEs (RR=1.64, 95%CI=1.28 to 2.10, P<0.01). …”
  15. 19835

    Table_2_Effect and Safety of Adding Metformin to Insulin Therapy in Treating Adolescents With Type 1 Diabetes Mellitus: An Updated Meta-Analysis of 10 Randomized Controlled Trials.... by Ying Liu (18461)

    Published 2022
    “…Results suggested that metformin significantly decreased the HbA1c level at 12 months (mean difference [MD])=-0.50, 95% confidence interval [CI]=-0.61 to -0.39, P < 0.01); BMI (kg/m<sup>2</sup>) at 3 months (MD=-1.05, 95%CI=-2.05 to -0.05, P=0.04); BMI z-score at 6 months (MD=-0.10, 95%CI=-0.14 to -0.06, P<0.01); and TIDD at 3 (MD=-0.13, 95%CI=-0.20 to -0.06, P<0.01), 6 (MD=-0.18, 95%CI=-0.25 to -0.11, P<0.01), and 12 (MD=-0.42, 95%CI=-0.49 to -0.35, P<0.01) months but significantly increased the risk of hypoglycemia events (risk ratio [RR]=3.13, 95%CI=1.05 to 9.32, P=0.04) and GIAEs (RR=1.64, 95%CI=1.28 to 2.10, P<0.01). …”
  16. 19836

    Neurons from Kidins220<sup>−/−</sup> mice showed normal post-tetanic potentiation and synaptic depression of evoked EPSCs. by Joachim Scholz-Starke (324807)

    Published 2013
    “…<p><b>A</b>) EPSCs recorded using a paired-pulse protocol (IPI = 50 ms) are presented before (left trace) and after (right trace) the application of a 1-s stimulation train at 40 Hz (middle trace). …”
  17. 19837
  18. 19838
  19. 19839
  20. 19840

    Use of canine-human comparative genomics and expression analysis to improve annotation of canine probesets. by Joseph Briggs (219262)

    Published 2011
    “…Red represents increased and green decreased log-fold expression compared to the mean of all other tissues.…”